Physician profile
David D Lee
NPI 1184774812
$4,184.32
in general payments reported to CMS, 2019-2025
28 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $328 · 2021: $61.58 · 2022: $604 · 2023: $979 · 2024: $632 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Travel and Lodging: $582 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.65 |
| Travel and Lodging | $581.52 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.22 | 2019-2025 | |
| Ovesco Endoscopy USA, INC. | $581.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $461.65 | 2019-2025 | Eohilia, Entyvio |
| Aimmune Therapeutics, INC. | $435.54 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.69 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $335.90 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Gilead Sciences, INC. | $261.15 | 2019-2024 | |
| Celgene Corporation | $189.10 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $87.18 | 2019 | |
| Genzyme Corporation | $83.83 | 2022-2025 | |
| Pfizer INC. | $83.17 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $82.79 | 2019-2022 | |
| Madrigal Pharmaceuticals | $77.88 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $59.00 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $52.07 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.10 | 2020-2025 | |
| Ucb, INC. | $43.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $42.18 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $32.64 | 2022 | |
| Celltrion USA INC. | $31.05 | 2025 | Vegzelma |
| Boston Scientific Corporation | $27.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.85 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $22.81 | 2025 | Iqirvo |
| Bioventus LLC | $21.92 | 2023 | Durolane |
| Amgen INC. | $20.49 | 2023 | Amjevita, Avsola |
| Qol Medical, LLC | $17.73 | 2020 | |
| Shire North American Group INC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.